Interaction Checker

Pazopanib interactions

Pazopanib (Votrient) has 257 documented interactions across the FDA labels and fact sheets we index: 148 major, 107 moderate, 2 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (148)

  • AbrocitinibJAK inhibitorMajor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

  • Alfuzosinalpha blockerMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • AmiodaroneantiarrhythmicMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Amitriptylinetricyclic antidepressantMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • AnagrelideQT-prolonging drugMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Antacids (Tums, Maalox, Mylanta)OTC productMajor

    If concomitant administration with a gastric acid-reducing agent cannot be avoided, consider short-acting antacids in place of PPIs and H2-receptor antagonists. (Pazopanib label, Drug interactions)

  • AprepitantCYP3A4 inhibitorMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • ArmodafinilCNS stimulantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • Arsenic trioxideQT-prolonging drugMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • AsenapineantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • AtazanavirantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Azithromycinmacrolide antibioticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • BosentanCYP3A4 inducerMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • CarbamazepineanticonvulsantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • CenobamateanticonvulsantMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • ChloroquineantimalarialMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • ChlorpromazineantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • CimetidineH2 blockerMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • CiprofloxacinfluoroquinoloneMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • CitalopramSSRIMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Clarithromycinmacrolide antibioticMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • ClobazambenzodiazepineMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • ClozapineantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • CyclosporineimmunosuppressantMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • DarunavirantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Darunavir and cobicistatantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Deferasiroxiron supplementMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • DeutetrabenazineVMAT2 inhibitorMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • DexamethasonecorticosteroidMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • Dexlansoprazoleproton pump inhibitorMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • Dextromethorphan and quinidineserotonergic drugMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Diltiazemcalcium channel blockerMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • DisopyramideantiarrhythmicMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • DofetilideantiarrhythmicMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • DronedaroneantiarrhythmicMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Droperidoldopamine antagonistMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • EfavirenzantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Erythromycinmacrolide antibioticMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • EscitalopramSSRIMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • EslicarbazepineanticonvulsantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • Esomeprazoleproton pump inhibitorMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • EtravirineantiretroviralMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • EverolimusimmunosuppressantMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • FamotidineH2 blockerMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • FingolimodimmunosuppressantMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • FlecainideantiarrhythmicMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • FlibanserinCNS depressantMajor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

  • Fluconazoleazole antifungalMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • FluoxetineSSRIMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • FosamprenavirantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • FosaprepitantCYP3A4 inhibitorMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • FosphenytoinanticonvulsantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • GranisetronQT-prolonging drugMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • GriseofulvinantifungalMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • HaloperidolantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • HydroxychloroquineQT-prolonging drugMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • HydroxyzineantihistamineMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Ibuprofen and famotidineNSAIDMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • IbutilideantiarrhythmicMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • IloperidoneantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • ImatinibCYP3A4 inhibitorMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • IsoniazidantibioticMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Itraconazoleazole antifungalMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Ketoconazoleazole antifungalMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Lansoprazoleproton pump inhibitorMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • LapatinibP-glycoprotein inhibitorMajor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

  • Ledipasvir and sofosbuvirantiviralMajor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

  • LenacapavirantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • LevofloxacinfluoroquinoloneMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • LoperamideQT-prolonging drugMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • LorlatinibCYP3A4 inducerMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • MethadoneopioidMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • MifepristoneCYP3A4 inhibitorMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Mirabegronbeta-adrenergic agonistMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • MitapivatCYP3A4 inducerMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • MitotaneCYP3A4 inducerMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • ModafinilCNS stimulantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • MoxifloxacinfluoroquinoloneMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Nafcillinpenicillin antibioticMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • Naproxen and esomeprazoleNSAIDMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • NefazodoneantidepressantMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • NevirapineantiretroviralMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • NilotinibQT-prolonging drugMajor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • NizatidineH2 blockerMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • OfloxacinfluoroquinoloneMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Olanzapine and fluoxetineantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Omeprazoleproton pump inhibitorMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • Omeprazole and sodium bicarbonateproton pump inhibitorMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • OndansetronQT-prolonging drugMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • OxcarbazepineanticonvulsantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • PaliperidoneantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Pantoprazoleproton pump inhibitorMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • PentamidineQT-prolonging drugMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • PerampanelanticonvulsantMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • PhenobarbitalbarbiturateMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • PhenytoinanticonvulsantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • PimavanserinantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • PimozideantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • PitolisantQT-prolonging drugMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Posaconazoleazole antifungalMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • PrimidoneanticonvulsantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • ProcainamideantiarrhythmicMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • PromethazineantihistamineMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Promethazine and codeineopioidMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Promethazine and dextromethorphanantihistamineMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • PropafenoneantiarrhythmicMajor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

  • QuetiapineantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • QuinidineantiarrhythmicMajor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

  • QuinineantimalarialMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Rabeprazoleproton pump inhibitorMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • RanitidineH2 blockerMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • RanolazineQT-prolonging drugMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • RifabutinantibioticMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • RifampinantibioticMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • RifapentineantibioticMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • RisperidoneantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • RitonavirantiretroviralMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Sodium bicarbonateantacidMajor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (Pazopanib label, Drug interactions)

  • Sofosbuvir and velpatasvirantiviralMajor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

  • SolifenacinanticholinergicMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Sotalolbeta blockerMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Suvorexantsedative-hypnoticMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • SuzetrigineCYP3A4 inducerMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • TacrolimusimmunosuppressantMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Tamoxifenselective estrogen receptor modulatorMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • TetrabenazineVMAT2 inhibitorMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • ThioridazineantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Ticagrelorantiplatelet agentMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • TolterodineanticholinergicMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • TopiramateanticonvulsantMajor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (Pazopanib label, Drug interactions)

  • Toremifeneselective estrogen receptor modulatorMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • TramadolopioidMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Tramadol and acetaminophenopioidMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • TrazodoneantidepressantMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • ValbenazineVMAT2 inhibitorMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • VardenafilPDE5 inhibitorMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • VenlafaxineSNRIMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • Verapamilcalcium channel blockerMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • Voriconazoleazole antifungalMajor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib label, Drug interactions)

  • ZiprasidoneantipsychoticMajor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib label, Drug interactions)

  • ZonisamideanticonvulsantMajor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (Pazopanib label, Drug interactions)

Moderate interactions (107)

  • Acebutololbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • AdenosineantiarrhythmicModerate

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (Pazopanib label, Warnings and precautions)

  • AliskirenantihypertensiveModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Amiloridepotassium-sparing diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Amlodipinedihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Amlodipine and atorvastatindihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Amlodipine and benazeprildihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Amlodipine and olmesartandihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Amlodipine and valsartandihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Atenololbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Atenolol and chlorthalidonebeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • AtorvastatinstatinModerate

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (Pazopanib label, Warnings and precautions)

  • Azilsartanangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • BenazeprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Benazepril and hydrochlorothiazideACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Betaxololbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Bisoprololbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Bisoprolol and hydrochlorothiazidebeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Candesartanangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Candesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • CaptoprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Carvedilolbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Chlorothiazidethiazide diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Chlorthalidonethiazide diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Clonidinealpha-adrenergic agonistModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Digoxindigitalis glycosideModerate

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (Pazopanib label, Warnings and precautions)

  • Doxazosinalpha blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • EnalaprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Enalapril and hydrochlorothiazideACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • EnalaprilatACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Eplerenonealdosterone antagonistModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Esmololbeta blockerModerate

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (Pazopanib label, Warnings and precautions)

  • Ethacrynic acidloop diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Ezetimibe and simvastatinstatinModerate

    Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (Pazopanib label, Warnings and precautions)

  • Felodipinedihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • FluvastatinstatinModerate

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (Pazopanib label, Warnings and precautions)

  • FosinoprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Fosinopril and hydrochlorothiazideACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Furosemideloop diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Guanfacinealpha-adrenergic agonistModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • HydralazinevasodilatorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Hydrochlorothiazidethiazide diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Indapamidethiazide diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Irbesartanangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Irbesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Isosorbide dinitrate and hydralazinenitrateModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Isradipinedihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Labetalolbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Levothyroxinethyroid hormoneModerate

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (Pazopanib label, Warnings and precautions)

  • Levothyroxine and liothyroninethyroid hormoneModerate

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (Pazopanib label, Warnings and precautions)

  • Lidocainelocal anestheticModerate

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (Pazopanib label, Warnings and precautions)

  • Lidocaine and prilocainelocal anestheticModerate

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (Pazopanib label, Warnings and precautions)

  • Liothyroninethyroid hormoneModerate

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (Pazopanib label, Warnings and precautions)

  • LisinoprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Lisinopril and hydrochlorothiazideACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Lofexidinealpha-adrenergic agonistModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • LomitapideModerate

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (Lomitapide label, Drug interactions)

  • Losartanangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Losartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • LovastatinstatinModerate

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (Pazopanib label, Warnings and precautions)

  • MecamylamineantihypertensiveModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Methimazoleantithyroid drugModerate

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (Pazopanib label, Warnings and precautions)

  • MethyldopaantihypertensiveModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Metolazonethiazide diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Metoprololbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Metoprolol and hydrochlorothiazidebeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • MexiletineantiarrhythmicModerate

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (Pazopanib label, Warnings and precautions)

  • MinoxidilvasodilatorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • MoexiprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Nadololbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Nebivololbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Nicardipinedihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Nifedipinedihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Nisoldipinedihydropyridine calcium channel blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • NitroprussidevasodilatorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Olmesartanangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Olmesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Olmesartan, amlodipine, and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • PemetrexedantimetaboliteModerate

    Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality. (Pazopanib label, Warnings and precautions)

  • PerindoprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Phenoxybenzaminealpha blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Pindololbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • PitavastatinstatinModerate

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (Pazopanib label, Warnings and precautions)

  • PravastatinstatinModerate

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (Pazopanib label, Warnings and precautions)

  • Prazosinalpha blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Propranololbeta blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Propylthiouracilantithyroid drugModerate

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (Pazopanib label, Warnings and precautions)

  • QuinaprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Quinapril and hydrochlorothiazideACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • RamiprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • RosuvastatinstatinModerate

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (Pazopanib label, Warnings and precautions)

  • Sacubitril and valsartanangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • SimvastatinstatinModerate

    Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (Pazopanib label, Warnings and precautions)

  • Spironolactonealdosterone antagonistModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Spironolactone and hydrochlorothiazidealdosterone antagonistModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Telmisartanangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Telmisartan and amlodipineangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Telmisartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Terazosinalpha blockerModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Teriparatidethyroid hormoneModerate

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (Pazopanib label, Warnings and precautions)

  • Tizanidinemuscle relaxantModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Torsemideloop diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • TrandolaprilACE inhibitorModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Triamterenepotassium-sparing diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Triamterene and hydrochlorothiazidepotassium-sparing diureticModerate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Valsartanangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

  • Valsartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib label, Warnings and precautions)

Minor mentions (2)

  • BevacizumabMinor

    Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (Pazopanib label, Warnings and precautions)

  • TopotecanMinor

    Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (Pazopanib label, Warnings and precautions)

Check Pazopanib against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.